News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Cellectis confident on 'off the shelf' CAR-Ts despite setbac... US hospitals struggle to provide approved autologous therapies
News Pfizer's rituximab biosimilar gets late-stage trial boost Phase 3 success sets up showdown with Roche, Sandoz, and Celltrion
News Biotech association steps in to fight growth of ‘plausibilit... The UK’s Supreme Court is to allow the UK BioIndustry Association (BIA) to intervene in a long-running legal battle over a drug patent.
News Pharma collaborates to improve chances of NICE backing Duche... Project will initially focus on DMD but could benefit other rare diseases
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.